Siegfried at a Glance. March 2018

Transcription

1 Siegfried at a Glance March 2018

2 Who are we? Company founded 140 years ago Long-term tradition of pharmaceutics and chemicals Unique selling proposition (USP): development and manufacturing services of chemical and pharmaceutical industry Production of active pharmaceutical ingredients (API), intermediates and Drug Products Total number of employees: Approx (as of Dec 31, 2017) World-class integrated service partner regarding Quality and Compliance Listed on the Swiss Stock Exchange SIX Financially independent and robust Siegfried at a Glance 2

3 Why Siegfried? Bringing together our more than 140 years Pharma and Chemical heritage, we offer as an integrated partner benefit to our customers with more synergy, expertise and value Integrated supply of APIs and finished products Toughened stance by FDA: Siegfried for several years inspected with «no action indicated» Siegfried at a Glance 3

4 Siegfried s Growth Builds on Three Distinct Businesses Tailor-Made for Four Target Business Segments Underlying business models: Contract development and manufacturing In-house development Co-development Siegfried at a Glance 4

5 Our Vision Siegfried is a world-class integrated service partner to the global pharmaceutical industry in the development and manufacture of Drug Substances and Drug Products that improve life. Siegfried at a Glance 5

6 A Multinational Company with Manufacturing Assets in Europe, North America and Asia Siegfried at a Glance 6

7 History Siegfried at a Glance 7

8 History 1873 Pharmacist Samuel Benoni Siegfried founds a company with 12 employees as a supplier to pharmacies 1904 Conversion into a joint stock corporation 1928 Founding of Ganes Chemical Works, Inc. (NJ, USA) 1973 Quotation on the Swiss Stock Exchange (SWX) in Basel 1991 Focus on development and custom manufacturing Siegfried at a Glance 8

9 History 2001 Building of two core divisions: Siegfried and Sidroga Integration of Ganes into the Siegfried Group = Siegfried (USA) Inc Acquisition of Penick Corporation in New Jersey (USA) 2007 Launch of a new pharmaceutical production facility in Malta Sale of the Sidroga Division Sale of the biotech activities 2008 Sale of the pharmaceutical production site Zofingen Siegfried at a Glance 9

10 History 2010 Definition of new strategy Transform 2012 Acquisition of Alliance Medical Products (AMP) in Irvine (CA, USA) 2013 Construction of new production site Nantong (CN) and Zofingen (CH) 2014 Acquisition of Hameln Pharma in Hameln (DE) 2015 Acquisition of BASF sites in Minden (DE), Evionnaz (CH) and St. Vulbas (FR) 2016 Definition of new strategy Evolve 2018 Acquisition of the drug product manufacturing facility of Arena in Zofingen (CH) Siegfried at a Glance 10

11 Management Siegfried at a Glance 11

12 Organizational Chart Siegfried Group Siegfried at a Glance 12

13 Management Board of Directors Dr. Andreas Casutt Chairman Prof. Dr. Wolfram Carius Dr. Martin Schmid Vice Chairman Reto A. Garzetti Colin Bond Ulla Schmidt Siegfried at a Glance 13

14 Management Executive Committee Dr. Rudolf Hanko Chief Executive Officer Arnoud M. Middel Global Head Human Resources Dr. Reto Suter Chief Financial Officer Dr. René Imwinkelried Global Technical Operations Marianne Späne Head Business Development, Marketing & Sales Dr. Wolfgang Wienand Chief Scientific and Strategy Officer Siegfried im Überblick 14

15 Human Resources Siegfried at a Glance 15

16 Human Resources Vision Socially responsible employer Motivated and talented personnel Mutual respect Entrepreneurial thinking and acting Personal responsibility Focusing on results Open and transparent communication Performance-oriented company culture Siegfried at a Glance 16

17 Human Resource Development Employees per December 31, 2017 Location Number of employees Zofingen 543 Pennsville 159 Malta 128 Irvine 112 Nantong 204 Hameln 441 Minden 336 Evionnaz 298 St. Vulbas 110 Total 2331 Siegfried at a Glance 17

18 Financials Siegfried at a Glance 18

19 Net Sales CHF million Change CHF (LC) Drug Substances % Drug Products % Total % Siegfried at a Glance 19

20 Sales Drug Substances and Drug Products Total sales in the business year 2017 broken down into Drug Substances and Drug Products Drug Substances (77%) Drug Products (23%) Siegfried at a Glance 20

21 Business Development Net sales (in CHF million) Siegfried at a Glance 21

22 Business Development Share price development from January 1, 2013 to December 31, 2017 Siegfried at a Glance 22

23 Alignment of Shareholders, Board of Directors, Executive Committee and Management Team as Key for Success Shareholder structure ExeCom/BoD Management RAG-Stiftung Tweedy Browne Credit Suisse Funds KSK Biberach Norges Bank RMF Public Siegfried at a Glance 23

24 Strategy Siegfried at a Glance 24

25 Growth Evolve Strategy for : Siegfried Will Further Enhance its Pure-play CDMO Business Model Fields of action Strengthen offerings: Expand global solida drug product footprint Expand overall presence with own production facilities (e.g. US) Enhance development setup Grow within value chain of existing business: Reach critical size in drug product sector Backward integration Diversify into adjacent new business: Enhance technology base (micronization, lyophilization, spray drying, additional high-potent manufacturing capabilities) Siegfried at a Glance 25

26 Objectives of Evolve : Siegfried Remains Market Leader in the CDMO Business for Drug Substances Selected Players < 10 Strategic pharma partners Mid-sized standard suppliers ~50 "1-project" CMO shops > 500 Siegfried at a Glance 26

27 Thank You! Siegfried at a Glance 27